References

vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues

10.1007/s40264-013-0131-x · 2013 · External reference

Progress in immunization safety monitoring — worldwide, 2020–2022

10.15585/mmwr.mm7249a2 · 2023 · External reference

VigiBase: resource profile update with a summary of global patterns and trends in adverse event reports for medicines and vaccines

10.1007/s40264-025-01642-6 · 2026 · External reference

About the vaccine adverse event reporting system (VAERS)

2026 · External reference

Educational interventions in pharmacovigilance to improve the knowledge, attitude and the report of adverse drug reactions in healthcare professionals: Systematic review and Meta-analysis

10.1007/s40199-024-00508-z · 2024 · External reference

Factors associated with underreporting of adverse drug reactions by patients: a systematic review

10.1007/s11096-023-01592-y · 2023 · External reference

Interplay of spontaneous reporting and longitudinal healthcare databases for signal management: position statement from the real-world evidence and big data special interest group of the international society of pharmacovigilance

10.1007/s40264-025-01548-3 · 2025 · External reference

Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems

10.3389/fdsfr.2023.1323057 · 2024 · External reference

Completeness of spontaneously reported adverse drug reactions in 4 databases

10.1002/bcp.70182 · 2025 · External reference

Pharmacist-led deprescribing interventions for older adults with polypharmacy: a retrospective cohort study of community pharmacy practice in Japan

10.1007/s40266-025-01275-5 · 2026 · External reference

Medication use quality and safety in older adults: 2023 update

10.1111/jgs.19360 · 2025 · External reference

Understanding the landscape of cancer care in Europe: evaluating clinical and comprehensive cancer centers

10.3390/healthcare12232338 · 2024 · External reference

Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review

10.1002/pds.5768 · 2024 · External reference

Evaluation of the direct costs of managing adverse drug events in all ages and of avoidable adverse drug events in older adults in Japan

10.3389/fphar.2021.761607 · 2021 · External reference

Integrating electronic health records with other data sources for postmarket drug safety signal identification: a review

10.3389/fdsfr.2024.1428831 · 2024 · External reference

Sex differences in adverse drug reactions: are women more impacted?

10.1016/j.therap.2022.10.002 · 2023 · External reference

VigiBase, the WHO global ICSR database system: basic facts

10.1177/009286150804200501 · 2008 · External reference

Cross-national pharmacovigilance of drug-induced intestinal obstruction: disproportionality signals in FAERS and external validation in JADER

10.3389/fphar.2026.1760208 · 2026 · External reference

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

10.3389/fphar.2024.1485190 · 2024 · External reference

Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation

10.1177/20420986241228119 · 2024 · External reference

Polypharmacy in elderly patients in Japan: analysis of Japanese real-world databases

10.1111/jcpt.13122 · 2020 · External reference

FDA adverse event reporting system: recruiting doctors to make surveillance a little less passive

2015 · External reference

Trends in adverse drug reaction reporting in eight selected countries after the implementation of new pharmacovigilance regulation in 2012: a joinpoint regression analysis

10.1007/s00228-025-03862-2 · 2025 · External reference

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-Fusion positive solid tumors, and venetoclax for leukemia

10.1007/s10147-025-02939-3 · 2026 · External reference

Adverse drug reactions in multimorbid older people exposed to polypharmacy: epidemiology and prevention

10.3390/pharma3020013 · 2024 · External reference

Influence of differential source patterns in the detection of signals of disproportionate reporting for PARP inhibitors

10.3389/fdsfr.2024.1497116 · 2024 · External reference

HIV epidemiology, prevention, treatment, and implementation strategies for public health

10.1016/s0140-6736(23)01381-8 · 2024 · External reference

Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events

10.1038/s41598-023-46275-w · 2023 · External reference

Global HIV control: is the glass half empty or half full?

10.1016/s2352-3018(23)00150-9 · 2023 · External reference

Treatments for elderly cancer patients and reforms to social security systems in Japan

10.1007/s10147-021-02099-0 · 2022 · External reference

Cancer prevalence projections in Japan and decomposition analysis of changes in cancer burden, 2020–2050: a statistical modeling study

10.1158/1055-9965.epi-23-0754 · 2023 · External reference

Health at a glance: Asia/Pacific 2024

2024 · External reference

Unresolved reference

2026 · External reference

Association between polypharmacy and adverse events in patients with alzheimer’s disease: an analysis of the Japanese adverse drug event report database (JADER)

10.3390/medicina60101633 · 2024 · External reference

Drug safety in healthy aging

10.1038/s41514-025-00220-5 · 2025 · External reference

Descriptive analysis on disproportionate medication errors and associated patient characteristics in the food and drug Administration’s adverse event reporting system. Pharmacoepidemiol

10.1002/pds.5743 · 2024 · External reference

Disproportionality analysis and characterisation of medication errors in EudraVigilance: exploring findings on sexes and age groups

10.1007/s40264-024-01478-6 · 2025 · External reference

Unresolved reference

2026 · External reference

FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS

10.1002/cpt.3701 · 2025 · External reference

Unresolved reference

External reference

Temporal and geographical trends in anticoagulant therapy and catheter ablation for atrial fibrillation in Japan, 2014–2022

10.1016/j.jjcc.2025.07.008 · 2025 · External reference

Timing matters: exploring the role of the time to onset in recall bias for adverse events following immunization (AEFIs) of COVID-19 vaccines from spontaneous reports

10.3390/pharma4020008 · 2025 · External reference

Choosing thresholds for statistical signal detection with the proportional reporting ratio

10.1007/s40264-013-0075-1 · 2013 · External reference

Serious adverse drug events reported to the FDA: analysis of the FDA adverse event reporting system 2006-2014 database

10.18553/jmcp.2018.24.7.682 · 2018 · External reference

Sex and gender differences and pharmacovigilance: a knot still to be untied

10.3389/fphar.2024.1397291 · 2024 · External reference

Oral anticoagulant therapy in older adults

10.1016/j.thromres.2024.04.009 · 2024 · External reference

Characteristics and patterns of adverse event reports in the Japanese adverse drug event report database over two decades (2004-2023): exploring findings on sexes and age groups

10.5582/ddt.2024.01090 · 2025 · External reference

Methodological approaches for analyzing medication error reports in patient safety reporting systems: a scoping review

10.1016/j.jcjq.2024.10.005 · 2025 · External reference

Changes in the trend and quality of adverse drug reaction reports in the Japanese adverse drug event report database and the impact of COVID-19-related reports

10.1093/ijpp/riaf084 · 2025 · External reference

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese adverse drug event report database

10.1002/bcp.70291 · 2026 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Monitoring vaccine safety: united States vaccine safety surveillance systems

10.1016/j.pedhc.2025.07.016 · 2026 · External reference